| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
WAY-301398 targets Protein Kinase C (PKC), a family of serine/threonine kinases that play critical roles in various cellular signaling pathways. It binds to PKC with a quantifiable affinity, establishing it as a specific chemical probe. Its documented activity in amyloid and synucleinopathy pathways makes it suitable for neurodegenerative disease research. Unlike broad-spectrum inhibitors, it is a specific binder for PKC.
|
|---|---|
| ln Vitro |
In vitro, WAY-301398 functions as a ligand for Protein Kinase C (PKC) with an IC50 of 120 nM. It is a bioactive molecule used for studying amyloid diseases and synucleinopathies. The compound has high DMSO solubility (58 mg/mL), facilitating concentrated stock preparation. It is frequently used as a pharmacological tool in in vitro experimental models.
|
| ln Vivo |
Specific in vivo data for WAY-301398 are not extensively reported. As a chemical probe for studying PKC in the context of neurodegenerative diseases, it would have potential for in vivo studies in animal models of amyloid diseases and synucleinopathies. However, specific published in vivo protocols for this compound are not detailed in the available literature.
|
| Enzyme Assay |
The PKC binding affinity of WAY-301398 is assessed using biochemical binding assays. Recombinant PKC protein is incubated with a radiolabeled or fluorescently labeled probe and various concentrations of WAY-301398. The displacement of the probe is measured, and the IC50 or Ki value is calculated from dose-response curves. The compound has a quantifiable PKC affinity of IC50 120 nM.
|
| Cell Assay |
For cellular studies, appropriate cell lines (e.g., neuronal cells) are cultured in suitable media. Cells are treated with WAY-301398 at various concentrations for 24-72 hours. Cell viability is assessed using MTT or similar assays. PKC activity is assessed by measuring the phosphorylation of downstream substrates via Western blot. The compound is soluble in DMSO (58 mg/mL, 201.2 mM) and ethanol (7 mg/mL) but insoluble in water.
|
| Animal Protocol |
In vivo studies for WAY-301398 would be conducted in appropriate animal models of amyloid diseases and synucleinopathies. The compound would be administered via intraperitoneal injection or oral gavage. However, specific published protocols for this compound are not available. For in vivo use, it can be formulated as a homogeneous suspension using CMC-Na.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for WAY-301398 are not extensively reported. The compound has a molecular formula of C16H13FO4 and a molecular weight of 288.27 g/mol. It is soluble in DMSO at 58 mg/mL (201.2 mM). The powder is stable for 3 years when stored at -20°C. Specific toxicological data for WAY-301398 are not reported. As a research compound, comprehensive toxicology studies have not been published. The compound is for research use only and not for human therapeutic use. Standard safety precautions should be taken when handling.
|
| Toxicity/Toxicokinetics |
WAY-301398 is a synthetic fluorinated aromatic diketone that functions as a PKC ligand with an IC50 of 120 nM. It is used as a chemical probe for studying neurodegenerative diseases, particularly amyloid diseases and synucleinopathies. Molecular formula: C16H13FO4, molecular weight: 288.27 g/mol. No clinical trials exist. For research use only.
|
| Molecular Formula |
C16H13FO4
|
|---|---|
| Molecular Weight |
288.27
|
| Exact Mass |
288.079
|
| CAS # |
312607-68-4
|
| PubChem CID |
768764
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
471.0±40.0 °C at 760 mmHg
|
| Flash Point |
238.7±27.3 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
3.48
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
377
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C=CC(=CC=1)C(CC(C1C=C(C=CC=1O)OC)=O)=O
|
| InChi Key |
ABKONMXONQQXKA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13FO4/c1-21-12-6-7-14(18)13(8-12)16(20)9-15(19)10-2-4-11(17)5-3-10/h2-8,18H,9H2,1H3
|
| Chemical Name |
1-(4-fluorophenyl)-3-(2-hydroxy-5-methoxyphenyl)propane-1,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4690 mL | 17.3449 mL | 34.6897 mL | |
| 5 mM | 0.6938 mL | 3.4690 mL | 6.9379 mL | |
| 10 mM | 0.3469 mL | 1.7345 mL | 3.4690 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
